Background and Objectives: Non‐alcoholic steatohepatitis (NASH) has become the leading indication for liver transplantation in many countries, with a growing rate in the Western world. NASH patients are older and share a higher risk of comorbidities and cancer than patients with viral and/or alcoholic etiologies. The aims of this study were to evaluate waiting list (WL) registration and liver transplantation rates in patients with NASH‐related cirrhosis at Padua University Hospital in the last fifteen years (1.2006–6.2020) and to compare clinical characteristics and indications for liver transplantation between patients with and without NASH, as well as the WL survival and post‐transplant outcome. Materials and Methods: All adult patients with cirrhosis listed for liver transplantation at Padua University Hospital between 1.2006 and 6.2020 were retrospectively col-lected using a prospectively updated database; patients with NASH‐related cirrhosis were divided by indication for liver transplantation (Dec‐NASH vs. hepatocellular carcinoma (HCC)‐NASH) and compared with patients with other etiologies of liver disease. The outcomes in terms of waiting list survival and post‐transplant outcome were assessed. Results: One thousand four hundred and ninety‐one adult cirrhotic patients were waitlisted during the study period. NASH patients ac-counted for 12% of all WL registrations, showing an increasing trend over time (from 2.5% in 2006 to 23% in 2020). In the last five years, NASH was the third, but most rapidly growing, indication for liver transplantation at our center. This trend was confirmed both for patients with decompensated cirrhosis (from 1.8% to 18%) and HCC as leading indication for transplantation (from 4% to 30%). NASH patients were older than non‐NASH ones (mean ± SD age 59 ± 9 vs. 56 ± 9 years; p < 0.01), whereas no difference was found in gender or Child‐Pugh of the model for end‐stage liver disease score at WL registration. A majority (60.9%) of NASH patients underwent liver transplantation, showing 1‐, 5‐ and 10‐y post‐transplant survivals of 86%, 73% and 60%, respectively. Conclusion: NASH cirrhosis has become a rapidly growing indication for liver transplantation at our center, both for HCC and decompensated disease, with good post‐transplant survival.

Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy

Battistella S.;Germani G.;Russo F. P.;Senzolo M.;Gambato M.;Vitale A.;Cillo U.;Burra P.
2022

Abstract

Background and Objectives: Non‐alcoholic steatohepatitis (NASH) has become the leading indication for liver transplantation in many countries, with a growing rate in the Western world. NASH patients are older and share a higher risk of comorbidities and cancer than patients with viral and/or alcoholic etiologies. The aims of this study were to evaluate waiting list (WL) registration and liver transplantation rates in patients with NASH‐related cirrhosis at Padua University Hospital in the last fifteen years (1.2006–6.2020) and to compare clinical characteristics and indications for liver transplantation between patients with and without NASH, as well as the WL survival and post‐transplant outcome. Materials and Methods: All adult patients with cirrhosis listed for liver transplantation at Padua University Hospital between 1.2006 and 6.2020 were retrospectively col-lected using a prospectively updated database; patients with NASH‐related cirrhosis were divided by indication for liver transplantation (Dec‐NASH vs. hepatocellular carcinoma (HCC)‐NASH) and compared with patients with other etiologies of liver disease. The outcomes in terms of waiting list survival and post‐transplant outcome were assessed. Results: One thousand four hundred and ninety‐one adult cirrhotic patients were waitlisted during the study period. NASH patients ac-counted for 12% of all WL registrations, showing an increasing trend over time (from 2.5% in 2006 to 23% in 2020). In the last five years, NASH was the third, but most rapidly growing, indication for liver transplantation at our center. This trend was confirmed both for patients with decompensated cirrhosis (from 1.8% to 18%) and HCC as leading indication for transplantation (from 4% to 30%). NASH patients were older than non‐NASH ones (mean ± SD age 59 ± 9 vs. 56 ± 9 years; p < 0.01), whereas no difference was found in gender or Child‐Pugh of the model for end‐stage liver disease score at WL registration. A majority (60.9%) of NASH patients underwent liver transplantation, showing 1‐, 5‐ and 10‐y post‐transplant survivals of 86%, 73% and 60%, respectively. Conclusion: NASH cirrhosis has become a rapidly growing indication for liver transplantation at our center, both for HCC and decompensated disease, with good post‐transplant survival.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3444824
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact